Onxeo Provides Update on Litigation with SpeBio/SpePharm

Paris (France), January 23, 2018 – 09:30 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), (“Onxeo” or the “Company”), a biotechnology company specializing in the development of innovative drugs in oncology, and notably rare and resistant forms of cancer, announces that it has submitted its conclusions to the Paris Court of Appeal concerning merits of the litigation against SpePharm/SpeBio B.V companies to ensure that the appeals process proceeds as expeditiously as possible for the benefit of its shareholders.

The Company will take all actions to convince the Court of Appeal of its legal position and the Court’s decision is expected as early as the end of Q4 2018.

In regards to the expected payment of the amounts determined by the Commercial Court of Paris on October 17, 2017, the Company is currently putting in place an action plan allowing to pursue its R&D programs as initially planned.

180123_PR_ONXEO_update SpeBio